Ultragenyx Pharmaceutical and Solid Biosciences have announced a strategic collaboration and license agreement to focus on the development and commercialisation of new gene therapies for Duchenne. The collaboration brings together Solid’s expertise in muscle biology...
Santhera Pharmaceuticals has announced that partner ReveraGen Biopharma has completed a long-term, open-label extension study of 24 months duration with Vamorolone in patients with Duchenne muscular dystrophy. Including 6 months treatment in the preceding study,...
The Duchenne Research Fund is pleased to share that the KineDMD study has been extended into 2021/22. KineDMD is Dr Aldo Faisal’s ground-breaking artificial intelligence study at Imperial College London, in collaboration with Great Ormond Street Hospital, which...
Congratulations to Jessica and Martyn Jacobs who raised more than £3,300 through their Snowdonia trek to make a difference for all boys with Duchenne. We are so grateful for your support and look forward to putting the funds to great use. Click here to see our...
Thank you to Sam Baum and Avi Mocton for running the Jerusalem Marathon on Friday 15th March, raising money for the Duchenne Research Fund. A special thank you too, to Alex Klinger who unfortunately had to pull out due to injury but cheered on from the sidelines....
